1.Clinical Characteristics of Children with Hemophagocytic Syndrome with Different EB Virus DNA Loads.
Jiao-Jiao HUANG ; Nan-Du LUO ; Zuo-Chen DU ; Jia-Hong YAN ; Jin-Hua MA ; Xiu-Li CAO ; Zhi-Xu HE ; Pei HUANG ; Yan CHEN
Journal of Experimental Hematology 2023;31(1):261-267
		                        		
		                        			OBJECTIVE:
		                        			To analyze the clinical characteristics of hemophagocytic syndrome (HLH) children with different EB virus (EBV) DNA loads, and to explore the relationship between differential indicators and prognosis.
		                        		
		                        			METHODS:
		                        			Clinical data of 73 children with HLH treated in our hospital from January 2015 to April 2022 were collected. According to EBV DNA loads, the children were divided into negative group (≤5×102 copies/ml), low load group (>5×102-<5×105 copies/ml) and high load group (≥5×105copies/ml). The clinical symptoms and laboratory indexes of the three groups were compared, and the ROC curve was used to determine the best cut-off value of the different indexes. Cox regression model was used to analyze the independent risk factors affecting the prognosis of children, and to analyze the survival of children in each group.
		                        		
		                        			RESULTS:
		                        			The proportion of female children, the swelling rate of liver and spleen lymph nodes and the involvement rate of blood, liver, circulation and central nervous system in the high load group were higher than those in the negative group. The incidence of disseminated intravascular coagulation(DIC) and central nervous system(CNS) involvement in the high load group were higher than those in the low load group. The liver swelling rate and circulatory system involvement rate in the low load group were higher than those in the negative group(P<0.05). PLT counts in the high load group were significantly lower than those in the negative group, and the levels of GGT, TBIL, CK-MB, LDH, TG, SF, and organ involvement were significantly higher than those in the negative group. The levels of CK, LDH, SF and the number of organ involvement in the high load group were significantly higher than those in the low load group. The levels of GGT and TBIL in low load group were significantly higher than those in negative group. In terms of treatment, the proportion of blood purification therapy in the high and low load group was significantly higher than that in the negative group(P<0.01). ROC curve analysis showed that the best cut-off values of PLT, LDH, TG and SF were 49.5, 1139, 3.12 and 1812, respectively. The appellate laboratory indicators were dichotomized according to the cut-off value, and the differential clinical symptoms were included in the Cox regression model. Univariate analysis showed that LDH>1139 U/L, SF>1812 μg/L, dysfunction of central nervous system, number of organ damage, DIC and no blood purification therapy were the risk factors affecting the prognosis of children (P<0.05); Multivariate analysis shows that PLT≤49.5×109/L and dysfunction of central nervous system were risk factors affecting the prognosis of children (P<0.05). Survival analysis showed that there was no significant difference in the survival rate among the three groups.
		                        		
		                        			CONCLUSION
		                        			The incidence of adverse prognostic factors in children with HLH in the EBV-DNA high load group is higher, and there is no significant difference in the survival rate of the three groups after blood purification therapy. Therefore, early identification and application of blood purification therapy is of great significance for children with HLH in the high load group.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Lymphohistiocytosis, Hemophagocytic
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			DNA
		                        			;
		                        		
		                        			Prognosis
		                        			
		                        		
		                        	
2.Applicability of Seven Glomerular Filtration Rate Evaluation Formulas in Dose Adjustment of High Concentration of Methotrexate Chemotherapy in Children with ALL.
Fei LI ; Shan HUANG ; Xia-Xia ZHU ; Jing-Miao ZHANG ; Hong CHEN ; Xiu-Xia LIU ; Qing-Mei DENG
Journal of Experimental Hematology 2023;31(1):280-286
		                        		
		                        			OBJECTIVE:
		                        			To investigate the diagnostic efficacy of seven glomerular filtration rate (GFR) evaluation formulas Schwartz2009, Schwartz1976, Counahan-Barratt, Filler, CKD-EPIscysc, Cockrofi-Gault, CKD-EPIScysC-Scr in high concentration of methotrexate (HDMTX) chemotherapy dose adjusted cut-off point (GFR ≤85 ml/min) in children with acute lymphoblastic leukemia (ALL).
		                        		
		                        			METHODS:
		                        			One hundred and twenty-four children with ALL were included in the study. GFR determined by renal dynamic imaging (sGFR) was used as the standard to evaluate the accuracy, consistency of eGFR calculated by seven formulas and sGFR, and the diagnostic efficacy of each formula when the sGFR ≤85 ml/min boundary.
		                        		
		                        			RESULTS:
		                        			All of the accuracy of eGFR estimated by Schwartz2009 were greater than 70% in the 0-3, >4 and ≤6, >6 and ≤9, >9 and ≤16 years old group and male group, and the consistency exceeded the professional threshold. When the sensitivity of the ROC curve sGFR ≤85 ml/min was 100% of CKD-EPIscysc in the 0-3, >3 and ≤4 years old group, Filler in the >3 and ≤4 years old group, and Cockrofi-Gault in the >6 and ≤9 years old group, the specificity was 73.02%, 78.95%, 78.95%, 69.32%, respectively, and the AUC under the ROC curve was the largest (P<0.05).
		                        		
		                        			CONCLUSION
		                        			Schwartz2009 formula predicts the highest accuracy of eGFR in the 7 glomerular filtration rate. CKD-EPIscysc, Filler, and Cockrofi-Gault formulas have more guiding signi-ficance for the adjustment of HDMTX chemotherapy in pre-adolescence in children with ALL when sGFR ≤85 ml/min.
		                        		
		                        		
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Child, Preschool
		                        			;
		                        		
		                        			Glomerular Filtration Rate
		                        			;
		                        		
		                        			Methotrexate
		                        			;
		                        		
		                        			Creatinine
		                        			;
		                        		
		                        			Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*
		                        			;
		                        		
		                        			Renal Insufficiency, Chronic/diagnosis*
		                        			
		                        		
		                        	
3.Endoscopic retrograde cholangiopancreatography in patients after bilioenteric anstomosis.
Wei ZHENG ; Yong Hui HUANG ; Hong CHANG ; Wei YAO ; Ke LI ; Xiu E YAN ; Yao Peng ZHANG ; Ying Chun WANG ; Wen Zheng LIU
Journal of Peking University(Health Sciences) 2022;54(6):1178-1184
		                        		
		                        			OBJECTIVE:
		                        			To distinguish clinical features, safety and efficiency of endoscopic retrograde cholangiopancreatography (ERCP) in patients after bilioenteric anstomosis based on retrospectively analyzed clinical data and endoscopy procedures.
		                        		
		                        			METHODS:
		                        			Data extracted from patients after bilioenteric anstomosis due to biliary disease treated with ERCP from January 2005 to December 2021 in the Department of Gastroenterology, Peking University Third Hospital were retrospectively analyzed. Clinical data and endoscopic pictures were reevaluated and analyzed. The patients were divided into three groups, including the patients with choledochoduodenostomy (CDD), Roux-en-Y hepaticojejunostomy (RYHJ) and Whipple. Differences between ERCP success and failure were conducted.
		                        		
		                        			RESULTS:
		                        			In the study, 89 cases with 132 ERCP procedures were involved, 9-80 years old, median 57 years old, containing 4 CDD, 30 RYHJ, 54 Whipple and 1 bile duct ileocecal anastomosis patients; The time between ERCP and surgery were 30 (1-40), 2.75 (0.5-14), 2 (0.3-19), and 10 years, respectively; The time between surgery and symptom were 240 (3-360), 12 (1-156), 22 (0-216), and 60 months, respectively. Fifty percent of CDD could succeed only under local anaesthesia, RYHJ (96.7%) and Whipple (100.0%) needed under general anaesthesia (P < 0.001). Successful first entry rates of CDD, RYHJ and Whipple were 100.0%, 40.0% and 77.8%, respectively. After changing the endoscopy type, successful entry rate could increase to 43.3% of RYHJ and 83.3% of Whipple. The successful entry rate of different anastomotic methods was significant (P < 0.001). The cannulation success rates of CDD, RYHJ and Whipple were 100.0%, 53.8% and 86.7% respectively, with significant difference between the groups (P=0.031). ERCP success rates of CDD, RYHJ and Whipple were 100.0%, 33.3% and 78.8% respectively, with significant difference between the groups (P < 0.001). Complications were found in 23.9% (21/88) patients, including infection (14.8%), pancreatitis (9.2%), bleeding (3.4%), and perforation (2.3%) ranked by incidence. Causes of ERCP in post bilioenteric anstomosis were anastomotic stenosis (50.0%, benign 39.3%, malignant 10.7%), choledocholithiasis (37.5%) and reflux cholangitis (12.5%). Anastomotic method was the only predicting factor of ERCP success in patients after bilioenteric anstomosis (OR=7, 95%CI: 2.591-18.912, P < 0.001).
		                        		
		                        			CONCLUSION
		                        			ERCP in post bilioenteric anstomosis patients with gastrointestinal reconstruction need general anaesthe-sia, with good safety and efficiency. The successful rate of RYHJ was significantly lower than Whipple. Anastomotic method was the only predicting factor of ERCP success.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Young Adult
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Cholangiopancreatography, Endoscopic Retrograde/methods*
		                        			;
		                        		
		                        			Anastomosis, Roux-en-Y/methods*
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Intestine, Small
		                        			;
		                        		
		                        			Anastomosis, Surgical
		                        			
		                        		
		                        	
4.Governor vessel moxibustion combined with warming acupuncture for knee osteoarthritis with yang deficiency and cold congelation based on the supporting-yang theory.
Xiu-E HONG ; Lin-Yun ZHANG ; Wang LIN ; Yin-Ying LIN ; Qian-Lin LIN ; Ding-Yu ZHU ; Xin XU ; Ming-Xia WU
Chinese Acupuncture & Moxibustion 2022;42(12):1357-1362
		                        		
		                        			OBJECTIVE:
		                        			To compare the clinical efficacy between governor vessel moxibustion combined with warming acupuncture based on the supporting-yang theory and simple warming acupuncture for knee osteoarthritis (KOA) with yang deficiency and cold congelation.
		                        		
		                        			METHODS:
		                        			A total of 64 patients with KOA of yang deficiency and cold congelation were randomized into a combination group (32 cases, 2 cases dropped off) and a warming acupuncture group (32 cases, 1 case dropped off). In the warming acupuncture group, warming acupuncture was applied at Zusanli (ST 36), Guanyuan (CV 4) and Dubi (ST 35), Neixiyan (EX-LE 4), etc. on the affected side, once a day. On the basis of the treatment in the warming acupuncture group, governor vessel moxibustion was applied in the combination group, once a week. The 14-day treatment was taken as one course, and totally 2 courses with 2-day interval were required in the two groups. The clinical symptom score, the visual analogue scale (VAS) score and the Western Ontario and McMaster Universities arthritis index (WOMAC) score were observed before treatment, after treatment and in the follow-up of 12 weeks after treatment; the volume of suprapatellar bursa effusion was detected before and after treatment; the clinical efficacy was evaluated after treatment and in the follow-up in the two groups.
		                        		
		                        			RESULTS:
		                        			After treatment and in the follow-up, the scores of clinical symptom, VAS and WOMAC were decreased compared before treatment in both groups (P<0.05), and those in the combination group were lower than the warming acupuncture group (P<0.05). After treatment, the volume of suprapatellar bursa effusion was decreased compared before treatment in both groups (P<0.05). After treatment and in the follow-up, the total effective rates were 93.3% (28/30) and 86.7% (26/30) in the combination group, which were superior to 87.1% (27/31) and 74.2% (23/31) in the warming acupuncture group respectively (P<0.05).
		                        		
		                        			CONCLUSION
		                        			Governor vessel moxibustion combined with warming acupuncture can improve the clinical symptoms i.e. pain and dysfunction and reduce the volume of suprapatellar bursa effusion in KOA patients with yang deficiency and cold congelation, its short-term effect and long-term effect are both superior to simple warming acupuncture.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Universities
		                        			;
		                        		
		                        			Yang Deficiency/therapy*
		                        			
		                        		
		                        	
5.The Clinical Observation with Ruxolitinib as Graft-Versus-Host Disease Prophylaxis for Children with Thalassemia after Unrelated or Haploidentical Allo-Hematopoietic Stem Cell Transplantation.
Ya-Mei CHEN ; Xiu-Li HONG ; Jin-Zong LIN ; Jie SHI ; Quan-Yi LU
Journal of Experimental Hematology 2022;30(5):1586-1589
		                        		
		                        			OBJECTIVE:
		                        			To retrospectively analyze the efficacy and safety of ruxolitinib therapy for children with thalassemia after unrelated or haploidentical stem cell transplantation.
		                        		
		                        			METHODS:
		                        			From March 2020 to March 2021, 22 patients received successfully allogeneic hematopoietic stem cell transplantation in the Zhongshan Hospital of Xiamen University, from +30 to 100 days,those patients received ruxolitinib therapy (2.5 mg, twice daily) and all adverse reactions were observed, include aGVHD, cGVHD, CMV and EBV infection.
		                        		
		                        			RESULTS:
		                        			22 patients underwent allogeneic stem cell transplantation, 5 patients were diagnosed as aGVHD, 3 patients had grade I-II skin GVHD and 2 patients had grade II intestinal GVHD, those patients were cured. All patients were followed up for more than 21 weeks, 4 cases developed cGVHD, including 3 cases of localized liver GVHD and 1 case of pulmonary GVHD, those were relieved after active treatment. 8 patients had elevated EBV copies (>3×103/ml), and 3 patients had increased CMV copies, the patients recovered after immunosuppressant and antiviral treatment. There was no CMV infection and EBV related post-transplantant lymphoproliferative disorders(PTLD), and no transplant related deaths.
		                        		
		                        			CONCLUSION
		                        			Ruxolitinib can effectively reduce the incidence and severity of GVHD without affecting the hematopoietic recovery, and improve the survival status of thalassemia children after transplantation.
		                        		
		                        		
		                        		
		                        			Antiviral Agents/therapeutic use*
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Graft vs Host Disease/prevention & control*
		                        			;
		                        		
		                        			Hematopoietic Stem Cell Transplantation/adverse effects*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunosuppressive Agents/therapeutic use*
		                        			;
		                        		
		                        			Nitriles
		                        			;
		                        		
		                        			Pyrazoles
		                        			;
		                        		
		                        			Pyrimidines
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Thalassemia
		                        			
		                        		
		                        	
6.The Clinical Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation by Using Parental Donors in Patients with Thalassemia.
Han-Bing OU ; Jin-Zong LIN ; Xiu-Li HONG ; Jing-Yuan LU ; Quan-Yi LU
Journal of Experimental Hematology 2022;30(2):534-538
		                        		
		                        			OBJECTIVE:
		                        			To analyze the clinical efficacy of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) by using parental donors on thalassemia patients.
		                        		
		                        			METHODS:
		                        			The 13 thalassemia patients treated by haplo-HSCT using parental donors in our hospital from July 1, 2016, to July 1, 2020 were retrospectively reviewed. Hematopoiesis reconstitution, the incidence of GVHD, infections and the long-term survival of the patients were analyzed.
		                        		
		                        			RESULTS:
		                        			Twelve of the 13 patients were successfully implanted, the success rate of implantation was 92.3%. The median time of neutrophil and platelet engraftment was 12.5 days (range, 9-22 days) and 21 days (range,12-34 days), respectively. One patient achieved primary graft failure. Three (25%) patients developed to acute GVHD (aGVHD) and achieved complete remission after treatment. Chronic GVHD developed in three (25%) patients, one of them was extensive and under treatment, while one patient developed to severe bacterial infection (7.7%). CMV viremia was diagnosed in two patients (15.4%). There were no patients developed to CMV disease. Three (23.1%) patients achieved EB viremia after transplantation, one of them developed to EBV-related lymphocytic proliferative disease, while there were no patients showed invasive fungal infection. At the last follow-up, all patients survived, twelve of them were free from transfusion dependency. There were no transplant-related deaths. Projected overall and thalassemia-free survival at three years was 100% and 92.3%, respectively.
		                        		
		                        			CONCLUSION
		                        			The transplant protocol of haplo-HSCT by using parental donors in patients with thalassemia has reliable source of donors, high incidence of successful implantation and low incidence of GVHD, which can be used as an effective way to increase the source of donors in children with thalassemia.
		                        		
		                        		
		                        		
		                        			Child
		                        			;
		                        		
		                        			Cytomegalovirus Infections
		                        			;
		                        		
		                        			Graft vs Host Disease
		                        			;
		                        		
		                        			Hematopoietic Stem Cell Transplantation
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Parents
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Thalassemia/therapy*
		                        			;
		                        		
		                        			Transplantation Conditioning/methods*
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Viremia
		                        			
		                        		
		                        	
7.Comparision of Allogeneic Hematopoietic Stem Cell Transplantation between Children with Thalassemia of Different Ages.
Dong-Liang KANG ; Yong-Hong TAN ; Ya-Mei CHEN ; Jing-Yuan LU ; Jie SHI ; Xiu-Zhen YAN ; Quan-Yi LU
Journal of Experimental Hematology 2022;30(2):539-542
		                        		
		                        			OBJECTIVE:
		                        			To investigate the difference of therapeutic effects on children with thalassemia at different age after hematopoietic stem cell transplantation.
		                        		
		                        			METHODS:
		                        			The clinical data of children with thalassemia treated in our hospital were retrospectively analyzed. The children were divided into 2-5 years old group and 6-12 years old group. The success rate of implantation, transplant-related mortality, GVHD incidence, and other transplant-related complications, as well as thalassemia-free survival (TFS) were compared between the two groups.
		                        		
		                        			RESULTS:
		                        			The incidence of GVHD, hemorrhagic cystitis and severe oral mucositis after transplantation in the 2-5 years old group were significantly lower than those in the 6-12 years old group, while there was no statistically significant difference in the TFS between the two groups.
		                        		
		                        			CONCLUSION
		                        			Children in the low age (2-5 years old) group show fewer complications and higher quality of life after transplantation, therefore, stem cell transplantation at 2-5 years old is more conducive to rehabilitation of the children with thalassemia.
		                        		
		                        		
		                        		
		                        			Child
		                        			;
		                        		
		                        			Child, Preschool
		                        			;
		                        		
		                        			Graft vs Host Disease/complications*
		                        			;
		                        		
		                        			Hematopoietic Stem Cell Transplantation
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Quality of Life
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Thalassemia/therapy*
		                        			;
		                        		
		                        			beta-Thalassemia/therapy*
		                        			
		                        		
		                        	
8.Value of endoscopic retrograde cholangiopancreatography in pancreaticobiliary maljunction
Ke LI ; Kuijin XUE ; Hong CHANG ; Wei YAO ; Yaopeng ZHANG ; Xiu′e YAN ; Yonghui HUANG
Chinese Journal of Digestive Endoscopy 2021;38(11):871-875
		                        		
		                        			
		                        			Objective:To explore the clinical characteristics of pancreaticobiliary maljunction (PBM) and its disease spectrum, and to evaluate therapeutic endoscopic retrograde cholangiopancreatography (ERCP).Methods:Data of 52 PBM patients who received therapeutic ERCP procedures for abdominal pain, jaundice and fever in Department of Gastroenterology of Peking University Third Hospital from June 2006 to March 2021 were collected. The clinical characteristics, typing, the change of disease spectrum and ERCP procedures were analyzed.Results:Among 52 PBM patients, female was more common. Abdominal pain and jaundice were the most common clinical manifestations, among which 20 were type Ⅰ, 25 type Ⅱ and 7 type Ⅲ. Half patients had the choledochal cyst. The mean timespan from the first onset to the final diagnosis was 12.2 years. Twenty-four cases (46.2%) had changes in PBM disease spectrum. Among 69 ERCP procedures, 5 (7.2%) failed. Difficult cannulation rate was 34.6% (18/52), and 11 patients underwent advanced cannulation techniques, while it was 15.4% (657/4 275) in the conterpart non-PBM patients in the same period, with significant difference between them ( χ2=14.455, P<0.05). Multiple therapeutic ERCP techniques including endoscopic sphincterotomy, pancreatic stent placement, removal of stones from the duct were applied with the successful rate of 92.8% (64/69). The incidence of post-ERCP pancreatitis was 15.4% (8/52). Conclusion:The chief clinical problem may be changed over time in PBM patients. Although ERCP plays an important role in PBM and its disease spectrum, there may be a higher rate of difficult cannulation and postoperative complications.
		                        		
		                        		
		                        		
		                        	
9.Clinical Significance of Truncated Mutant ΔJBP of TET2 Gene in Patients with Acute Myeloid Leukemia.
Yu-Chao YANG ; Ting XIA ; Ming LUO ; Wen-Zheng GUO ; Ling-Li ZHANG ; Xiu-Hua CHEN ; Zhi-Fang XU ; Hong-Wei WANG ; Yan-Hong TAN
Journal of Experimental Hematology 2021;29(4):1011-1018
		                        		
		                        			OBJECTIVE:
		                        			To the clinical characteristics and prognostic value of the patients with complete deletion of TET_JBP domain (ΔJBP) in TET2 acute myeloid leukemia (AML).
		                        		
		                        			METHODS:
		                        			Next Generation Sequencing technology was used to determine the mutations of 34 AML-related genes (including TET2 gene). The I-TASSER tool was used to predict the tertiary structure of the full-length TET2 protein and TET_JBP structure deletion.
		                        		
		                        			RESULTS:
		                        			Among 38 AML patients with TET2 mutations, 22(57.9%) showed truncation mutations, of which 16 (72.7%) produced TET2ΔJBP truncation mutants. Protein structure prediction showed that the deletion of TET_JBP domain lead to the significant changes of tertiary structure in TET2 protein. Compared with the patients in non-ΔJBP group, the age of patients in ΔJBP group were older (63 vs 54 years old, P=0.047), and the occurrence rate of CEBPA double mutation (CEBPA
		                        		
		                        			CONCLUSION
		                        			AML patients with TET2ΔJBP truncation mutant shows lower CR rate, shorter EFS and OS after induction chemotherapy, which may be related to the poor prognosis, and co-mutation with CEBPA
		                        		
		                        		
		                        		
		                        			DNA-Binding Proteins/genetics*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Induction Chemotherapy
		                        			;
		                        		
		                        			Leukemia, Myeloid, Acute/genetics*
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Mutation
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Proto-Oncogene Proteins/genetics*
		                        			;
		                        		
		                        			Remission Induction
		                        			
		                        		
		                        	
10.Quantitative Analysis on Immunophenotype of CD34
Xi CHEN ; Fang-Gang REN ; Yao-Fang ZHANG ; Jing XU ; Ting XIA ; Jian-Mei CHANG ; Xiu-Hua CHEN ; Yan-Hong TAN ; Hong-Wei WANG ; Zhi-Fang XU
Journal of Experimental Hematology 2021;29(3):832-839
		                        		
		                        			OBJECTIVE:
		                        			To investigate the quantitative expression of immunophenotype of CD34
		                        		
		                        			METHODS:
		                        			Multi-parameter flow cytometry (FCM) was used to detect the proportion and mean fluorescence intensity (MFI) of each antigen of bone marrow CD34
		                        		
		                        			RESULTS:
		                        			Bone marrow blast cell proportion (P<0.01), RBC level (P<0.01), and Hb level (P<0.05) of high-risk MDS patients were higher, while EPO level (P<0.05) was lower than those of low-risk patients. The proportion of CD34
		                        		
		                        			CONCLUSION
		                        			The immunophenotype of CD34
		                        		
		                        		
		                        		
		                        			Antigens, CD34
		                        			;
		                        		
		                        			Bone Marrow
		                        			;
		                        		
		                        			Bone Marrow Cells
		                        			;
		                        		
		                        			Flow Cytometry
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunophenotyping
		                        			;
		                        		
		                        			Myelodysplastic Syndromes
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail